Advanced search
Publication Cover
Scandinavian Journal of Clinical and Laboratory Investigation Volume 62, 2002 - Issue 2
Submit an article Journal homepage
29
Views
6
CrossRef citations to date
0
Altmetric
Research Article

Non-viral mediated gene transfer of porphobilinogen deaminase into mammalian cells

A. Johansson Porphyria Centre Sweden, Department of Medical Laboratory Sciences and Technology, Division of Clinical Chemistry, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden;
,
C. Möller HemeBiotech A/S, Lidingo, Sweden
,
P. Gellerfors HemeBiotech A/S, Lidingo, Sweden
&
P. Harper Porphyria Centre Sweden, Department of Medical Laboratory Sciences and Technology, Division of Clinical Chemistry, Karolinska Institute, Huddinge University Hospital, Stockholm, Sweden;
Pages 105-113 | Published online: 08 Jul 2009

  • Kappas A, Sassa S, Galbraith RA, Nordmann Y. The porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic basis of inherited diseases. 7th ed. New York: McGrawHiIl; 1995. p. 2103-59.
  • Andersson C, Bjersing L, Lithner F. Acute intermittent porphyria increases the risk of liver cancer. Early diagnosis of the cancer and varying surgery may improve the prognosis. Lakartidningen 1998; 95: 3043-4.
  • Church SE, McCoIl KE, Moore MR, Youngs GR. Hypertension and renal impairment as complications of acute porphyria. Nephrol Dial Transplant 1992; 7: 986-90.
  • Grandchamp B, De Verneuil H, Beaumont C, Chretien S, Walter O, Nordmann Y. Tissue-specific expression of porphobilinogen deaminase. Two isoenzymes from a single gene. Eur J Biochem 1987; 162: 105-10.
  • Raich N, Romeo PH, Dubart A, Beaupain D, Cohen-Solal M, Goossens M. Molecular cloning and complete primary sequence of human erythrocyte porphobilinogen deaminase. Nucleic Acids Res 1986; 14: 5955-68.
  • Chretien S, Dubart A, Beaupain D, Raich N, Grandchamp B, Rosa J, Goossens M, Romeo PH. Alternative transcription and splicing of the human porphobilinogen deaminase gene result either in tissue-specific or in housekeeping expression. Proc Natl Acad Sei USA 1988; 85: 6-10.
  • Moore MR, McCoIl KE. Therapy of the acute porphyrias. Clin Biochem 1989; 22: 181-8.
  • Mustajoki P, Tenhunen R, Tokola O, Volin L. Heme therapy. Am J Med 1989; 86: 509-10.
  • Moreau-Gaudry F, Barbot C, Mazurier F, Mahon FX, Reiffers J, Ged C, de Verneuil H. Correction of the enzyme deficit of bone marrow cells in congenital erythropoietic porphyria by retroviral gene transfer. Hematol Cell Ther 1996; 38: 217-20.
  • Moreau-Gaudry F, Ged C, Barbot C, Mazurier F, Boiron JM, Bensidhoum M, Reiffers J, de Verneuil H. Correction of the enzyme defect in cultured congenital erythropoietic porphyria disease cells by retrovirus-mediated gene transfer. Hum Gene Ther 1995; 6: 13-20.
  • Moreau-Gaudry F, Mazurier F, Bensidhoum M, Ged C, de Verneuil H. Metabolic correction of congenital erythropoietic porphyria by retrovirusmediated gene transfer into Epstein-Barr virustransformed B-cell lines. Blood 1995; 85: 1449-53.
  • Mazurier F, Moreau-Gaudry F, Salesse S, Barbot C, Ged C, Reiffers J, de Verneuil H. Gene transfer of the uroporphyrinogen III synthase cDNA into haematopoietic progenitor cells in view of a future gene therapy in congenital erythropoietic porphyria. J Inherit Metab Dis 1997; 20: 247-57.
  • Kauppinen R, Glass IA, Aizencang G, Astrin KH, Atweh GF, Desnick RJ. Congenital erythropoietic porphyria: prolonged high-level expression and correction of the heme biosynthetic defect by retroviral-mediated gene transfer into porphyric and erythroid cells. MoI Genet Metab 1998; 65: 10-7.
  • Fontanellas A, Mazurier F, Moreau-Gaudry F, Belloc F, Ged C, de Verneuil H. Correction of uroporphyrinogen decarboxylase deficiency (hepatoerythropoietic porphyria) in Epstein-Barr virustransformed B-cell lines by retrovirus-mediated gene transfer: fluorescence-based selection of transduced cells. Blood 1999; 94: 465-74.
  • Pawliuk R, Bachelot T, Wise RJ, Mathews-Roth MM, Leboulch P. Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by preselective gene therapy. Nat Med 1999; 5: 768-73.
  • Lindberg RL, Porcher C, Grandchamp B, Ledermann B, Burki K, Brandner S, Aguzzi A, Meyer UA. Porhobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. Nat Genet 1996; 12: 195-9.
  • Johansson A, Blomberg P, Gellerfors P, Möller C, Harper P, Islam KD. 8th Meeting of the European Society of Gene Therapy (ESGT). Stockholm, Sweden, 7-10 October 2000. Abstracts. In: J Gene Med 2000;2 Suppl 5: 116.
  • Kozak M. An analysis of 5'-noncoding sequences from 699 vertebrate messenger RNAs. Nucleic Acids Res 1987; 15: 8125-48.
  • Beaumont C, Porcher C, Picat C, Nordmann Y, Grandchamp B. The mouse porphobilinogen deaminase gene. Structural organization, sequence, and transcriptional analysis. J Biol Chem 1989; 264: 14829-34.
  • Kauppinen R, Mustajoki S, Pihlaja H, Pettonen L, Mustajoki P. Acute intermittent porphyria in Finland: 19 mutations in the porphobilinogen deaminase gene. Hum MoI Genet 1995; 4: 215-22.
  • Mustajoki S, Laine M, Lahtela M, Mustajoki P, Peltonen L, Kauppinen R. Acute intermittent porphyria: expression of mutant and wild-type porphobilinogen deaminase in COS-1 cells. MoI Med 2000; 6: 670-9.
  • Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sei USA 1995; 92: 7297-301.
  • Magnussen CR, Levine JB, Doherty JM, Cheesman JO, Tschudy DP. A red cell enzyme method for the diagnosis of acute intermittent porphyria. Blood 1974; 44: 857-68.
  • Lentner C. Physical chemistry composition of blood hematology somatometric data. In: Geigy Scientific tables. 8th ed. Basle, Switzerland: CibaGeigy; 1984. p. 166-7.
  • Kichler A, Behr JP, Erbacher P. Polyethylenimines: a family of potent polymers for nucleic acid delivery. In: Huang L, Hung MC, Wagner E, editors. Nonviral vectors for gene therapy. San Diego: Academic Press; 1999. p. 191-206.
  • Boshart M, Weber F, Jahn G, Dorsch-Hasler K, Fleckenstein B, Schaffher W. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 1985; 41: 521-30.
  • Godbey WT, Barry MA, Saggau P, Wu KK, Mikos AG. Poly(ethylenimine)-mediated transfection: a new paradigm for gene delivery. J Biomed Mater Res 2000; 51: 321-8.
  • Boussif O, Zanta MA, Behr JP. Optimized galenics improve in vitro gene transfer with cationic molecules up to 1000-fold. Gene Ther 1996; 3:1074-80.
  • Godbey WT, Wu KK, Mikos AG. Tracking the intracellular path of poly(ethylenimine)/DNA complexes for gene delivery. Proc Natl Acad Sei USA 1999; 96: 5177-81.
  • Kichler A, Leborgne C, Coeytaux E, Danos O. Polyethylenimine-mediated gene delivery: a mechanistic study. J Gene Med 2001; 3: 135-44.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.